IRIS
metadata only
Iloperidone treatment mitigates the juvenile Huntington's disease phenotype possibly via Sigma‐1 receptor modulation
Juvenile Huntington's disease (jHD) is a severe genetic disorder with combined neurodegenerative and neurodevelopmental features, characterized by early onset and markedly reduced life expectancy. Despite extensive efforts, drug development has been largely unsuccessful and no effective therapy capa
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196#896852
- Huntington's Disease Young Adult Study 2.0#1245499
- Long Term Follow-up Grafted Huntington's Disease Patients#811042
- Cooperative Huntington's Observational Research Trial#979789
- PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD#879889
Record · ID 1313050
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive